203 related articles for article (PubMed ID: 33902495)
41. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC.
Wu C; Qi X; Qiu Z; Deng G; Zhong L
Aging (Albany NY); 2021 Sep; 13(18):22148-22163. PubMed ID: 34491228
[TBL] [Abstract][Full Text] [Related]
42. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
43. Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma.
Eun HS; Cho SY; Lee BS; Seong IO; Kim KH
Mol Med Rep; 2018 Dec; 18(6):4865-4876. PubMed ID: 30280198
[TBL] [Abstract][Full Text] [Related]
44. Prediction of Poor Prognosis of HCC by Early Warning Model for Co-Expression of miRNA and mRNA Based on Bioinformatics Analysis.
Su ZJ; Lin CC; Pan JH; Zhang JH; Han T; Pan Q
Technol Cancer Res Treat; 2020; 19():1533033820959353. PubMed ID: 33089765
[TBL] [Abstract][Full Text] [Related]
45. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
Abdelgawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
Asian Pac J Cancer Prev; 2013; 14(12):7345-9. PubMed ID: 24460300
[TBL] [Abstract][Full Text] [Related]
46. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma.
Hu B; Yang XB; Sang XT
Cancer Med; 2020 Oct; 9(20):7646-7662. PubMed ID: 32813933
[TBL] [Abstract][Full Text] [Related]
47. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
48. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
49. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.
Deng M; Sun S; Zhao R; Guan R; Zhang Z; Li S; Wei W; Guo R
Mol Med; 2022 Feb; 28(1):16. PubMed ID: 35123387
[TBL] [Abstract][Full Text] [Related]
50. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients.
Hu B; Yang XB; Sang XT
Int Immunopharmacol; 2021 Jan; 90():107164. PubMed ID: 33172741
[TBL] [Abstract][Full Text] [Related]
51. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma.
Zhang Y; Tang Y; Guo C; Li G
Aging (Albany NY); 2021 May; 13(9):12865-12895. PubMed ID: 33946043
[TBL] [Abstract][Full Text] [Related]
52. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
53. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review).
Montalbano M; Georgiadis J; Masterson AL; McGuire JT; Prajapati J; Shirafkan A; Rastellini C; Cicalese L
Oncol Rep; 2017 Mar; 37(3):1291-1300. PubMed ID: 28098909
[TBL] [Abstract][Full Text] [Related]
54. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.
Lu M; Kong X; Wang H; Huang G; Ye C; He Z
Oncotarget; 2017 Jan; 8(5):8775-8784. PubMed ID: 28060739
[TBL] [Abstract][Full Text] [Related]
55. Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Tian Z; Wang Z; Chen Y; Qu S; Liu C; Chen F; Ma L; Zhu J
Med Sci Monit; 2020 Mar; 26():e922159. PubMed ID: 32231177
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
57. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
58. Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients.
Mauro M; Ugo P; Walton Z; Ali S; Rastellini C; Cicalese L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446098
[TBL] [Abstract][Full Text] [Related]
59. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
